美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

CoLucid Pharmaceuticals, Inc.

46.53

0.0000

成交量：- -

成交额：- -

市值：8.97亿

市盈率：-13.52

高：46.53

开：46.53

低：46.53

收：46.53

52周最高：46.65

52周最低：5.26

股本：1,928.43万

流通股本：479.00万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.4400

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

CoLucid Pharmaceuticals, Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.colucid.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Colucid制药公司于2005年8月31日在美国特拉华州注册成立，2005年12月16日，公司收购了或独家授权了Eli Lilly的对特定临床和临床前项目的商业开发权以及知识产权。这是正在开发的创新和专有小分子的急性治疗偏头痛三期临床阶段的生物制药公司。该公司的候选产品使用的行动在过去二十年的第一个新的机制，它相信可以解决偏头痛患者，包括那些与心血管危险因素或稳定的心血管疾病和那些谁是不满现有疗法的未满足的需求。Lasmiditan，其先导候选产品，是一种口服的片剂用于治疗急性偏头痛成人不具有与最常用的治疗相关的临床局限性。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CLCD/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CLCD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","market":"US","secType":"STK","nameCN":"CoLucid Pharmaceuticals, Inc.","latestPrice":46.525,"timestamp":1488315600000,"preClose":46.525,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":4790000,"shares":19284290,"eps":-3.44,"marketStatus":"盘前交易","change":0,"latestTime":"02-24 08:43:24 EST","open":46.525,"high":46.525,"low":46.525,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.44,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"listingDate":1430884800000,"exchange":"NASDAQ","adjPreClose":46.525,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","floatShares":4790000,"roa":"--","roe":"--","lyrEps":0,"shares":19284290,"dividePrice":0,"high":46.525,"amplitude":0,"preClose":46.525,"low":46.525,"week52Low":5.2558,"pbRate":"--","week52High":46.65,"institutionHeld":0,"latestPrice":46.525,"eps":-3.44,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.44,"open":46.525,"prevYearClose":46.525},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLCD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-08-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.83,"name":null,"time":"","type":"earning","dateTimestamp":1470801600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-11","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.73,"name":null,"time":"","type":"earning","dateTimestamp":1462939200000,"reportTimeType":"","actualEps":-0.85},{"market":"US","date":"2016-03-02","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.66,"name":null,"time":"","type":"earning","dateTimestamp":1456894800000,"reportTimeType":"","actualEps":-0.74},{"market":"US","date":"2015-11-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.71,"name":null,"time":"","type":"earning","dateTimestamp":1447131600000,"reportTimeType":"","actualEps":-0.59},{"market":"US","date":"2015-08-12","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.4,"name":null,"time":"","type":"earning","dateTimestamp":1439352000000,"reportTimeType":"","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLCD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.colucid.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Colucid制药公司于2005年8月31日在美国特拉华州注册成立，2005年12月16日，公司收购了或独家授权了Eli Lilly的对特定临床和临床前项目的商业开发权以及知识产权。这是正在开发的创新和专有小分子的急性治疗偏头痛三期临床阶段的生物制药公司。该公司的候选产品使用的行动在过去二十年的第一个新的机制，它相信可以解决偏头痛患者，包括那些与心血管危险因素或稳定的心血管疾病和那些谁是不满现有疗法的未满足的需求。Lasmiditan，其先导候选产品，是一种口服的片剂用于治疗急性偏头痛成人不具有与最常用的治疗相关的临床局限性。","exchange":"NASDAQ","name":"CoLucid Pharmaceuticals, Inc.","nameEN":"CoLucid Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":null}}